![Da Jan Yang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Da Jan Yang
Director Ejecutivo en ASCENTAGE PHARMA GROUP INTERNATIONAL .
Cargos activos de Da Jan Yang
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ASCENTAGE PHARMA GROUP INTERNATIONAL | Director Ejecutivo | 01/05/2009 | - |
Presidente | 01/05/2009 | - | |
Fundador | 01/05/2009 | - | |
Presidente | 01/05/2009 | - | |
Ascentage Pharma Group Corp. Ltd.
![]() Ascentage Pharma Group Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group Corp. Ltd. is a Chinese biopharmaceutical company. The company is based in Hong Kong, Hong Kong. The company was founded by Shao Meng Wang. | Director/Miembro de la Junta | - | - |
Ascentage International Ltd. | Director/Miembro de la Junta | - | - |
Shanghai Yasheng Pharmaceutical Technology Co., Ltd. | Director/Miembro de la Junta | - | - |
Ascentage Pharma Group, Inc. | Director/Miembro de la Junta | - | - |
Jiangsu Ascentage Pharma Pty Ltd. | Director/Miembro de la Junta | - | - |
Ascentage Pharma Suzhou Co Ltd
![]() Ascentage Pharma Suzhou Co Ltd Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Suzhou Ascentage Pharma Co., Ltd. is a pharmaceutical company. Suzhou Ascentage Pharma Co., Ltd. is based in Suzhou, China. The Chinese company was founded in 2016 by Guang Feng Wang. The CEO is Da Jan Yang. | Director Ejecutivo | - | - |
Presidente | - | - |
Historial de carrera de Da Jan Yang
Antiguos cargos conocidos de Da Jan Yang.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Ascenta Therapeutics, Inc. (California) | Director/Miembro de la Junta | 01/01/2005 | 01/01/2008 |
Director Ejecutivo | 01/01/2005 | 01/01/2008 | |
Director Técnico/Científico/I+D | 01/01/2004 | 01/01/2008 | |
Fundador | 01/01/2004 | 01/01/2008 | |
Sun Yat-Sen University | Director/Miembro de la Junta | 01/09/2003 | 01/09/2006 |
Corporate Officer/Principal | 01/09/2003 | 01/09/2006 | |
░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formación de Da Jan Yang.
Michigan State University | Doctorate Degree |
Sun Yat-Sen University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
China | 5 |
Hong-Kong | 3 |
Operativa
Director/Board Member | 7 |
Chief Executive Officer | 3 |
Chairman | 2 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ASCENTAGE PHARMA GROUP INTERNATIONAL | Health Technology |
Empresas privadas | 9 |
---|---|
Ascenta Therapeutics, Inc. (California) | |
S*BIO Pte Ltd.
![]() S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Health Technology |
The Chinese Biopharmaceutical Association | |
Ascentage Pharma Group, Inc. | |
Jiangsu Ascentage Pharma Pty Ltd. | |
Ascentage International Ltd. | |
Shanghai Yasheng Pharmaceutical Technology Co., Ltd. | |
Ascentage Pharma Suzhou Co Ltd
![]() Ascentage Pharma Suzhou Co Ltd Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Suzhou Ascentage Pharma Co., Ltd. is a pharmaceutical company. Suzhou Ascentage Pharma Co., Ltd. is based in Suzhou, China. The Chinese company was founded in 2016 by Guang Feng Wang. The CEO is Da Jan Yang. | Health Technology |
Ascentage Pharma Group Corp. Ltd.
![]() Ascentage Pharma Group Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group Corp. Ltd. is a Chinese biopharmaceutical company. The company is based in Hong Kong, Hong Kong. The company was founded by Shao Meng Wang. | Health Technology |
- Bolsa de valores
- Insiders
- Da Jan Yang
- Experiencia